Tumor microenvironment: The culprit for ovarian cancer metastasis?

Siegel, 2015, Cancer statistics, 2015, CA Cancer J. Clin, 65, 5, 10.3322/caac.21254 Hudson, 2008, Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression, Clin. Exp. Metastasis, 25, 643, 10.1007/s10585-008-9171-5 Hennessy, 2009, Ovarian cancer, Lancet, 374, 1371, 10.1016/S0140-6736(09)61338-6 Yao, 2009, CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer, Oncol. Rep, 22, 541 Zhang, 2011, Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion, Cancer Lett, 303, 47, 10.1016/j.canlet.2011.01.011 Bhowmick, 2004, Stromal fibroblasts in cancer initiation and progression, Nature, 432, 332, 10.1038/nature03096 Koukourakis, 2006, Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma, Cancer Res, 66, 632, 10.1158/0008-5472.CAN-05-3260 Chen, 2009, TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected], Exp. Mol. Pathol, 87, 189, 10.1016/j.yexmp.2009.09.001 Orend, 2005, Potential oncogenic action of tenascin-C in tumorigenesis, Int. J. Biochem. Cell Biol, 37, 1066, 10.1016/j.biocel.2004.12.002 Wilson, 1999, Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines, Br. J. Cancer, 80, 685, 10.1038/sj.bjc.6690410 Schauer, 2011, Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer, Neoplasia, 13, 393, 10.1593/neo.101720 Pollard, 2009, Trophic macrophages in development and disease, Nat. Rev. Immunol, 9, 259, 10.1038/nri2528 Sica, 2008, Macrophage polarization in tumour progression, Semin. Cancer Biol, 18, 349, 10.1016/j.semcancer.2008.03.004 Mantovani, 2002, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, 23, 549, 10.1016/S1471-4906(02)02302-5 Farinha, 2005, Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL), Blood, 106, 2169, 10.1182/blood-2005-04-1565 Lissbrant, 2000, Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival, Int. J. Oncol, 17, 445 Tsutsui, 2005, Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density, Oncol. Rep, 14, 425 Takaishi, 2010, Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation, Cancer Sci, 101, 2128, 10.1111/j.1349-7006.2010.01652.x Negus, 1995, The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer, J. Clin. Invest, 95, 2391, 10.1172/JCI117933 Chambers, 1997, Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1, Clin. Cancer Res, 3, 999 Kawamura, 2009, Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors, Pathol. Int, 59, 300, 10.1111/j.1440-1827.2009.02369.x Lan, 2013, Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer, Technol. Cancer Res. Treat, 12, 259, 10.7785/tcrt.2012.500312 Le Page, 2012, BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis, PLoS ONE, 7, 10.1371/journal.pone.0038541 Kryczek, 2007, Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma, Cancer Res, 67, 8900, 10.1158/0008-5472.CAN-07-1866 Gastl, 2001, Bioactive interleukin-6 levels in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer, Methods Mol. Med, 39, 121 Mustea, 2009, Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study, Cytokine, 45, 8, 10.1016/j.cyto.2008.10.019 Hagemann, 2005, Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK, J. Immunol, 175, 1197, 10.4049/jimmunol.175.2.1197 Neyen, 2013, Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer, J. Immunol, 190, 3798, 10.4049/jimmunol.1203194 Wang, 2013, Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro, Cancer Sci, 104, 516, 10.1111/cas.12110 Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat. Med, 10, 942, 10.1038/nm1093 Kryczek, 2006, B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma, J. Exp. Med, 203, 871, 10.1084/jem.20050930 Allavena, 2010, Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages, Clin. Dev. Immunol, 2010, 547179, 10.1155/2010/547179 Barnett, 2010, Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype, Gynecol. Oncol, 116, 556, 10.1016/j.ygyno.2009.11.020 Cui, 2013, Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2, Immunity, 39, 611, 10.1016/j.immuni.2013.08.025 Liston, 2014, Homeostatic control of regulatory T cell diversity, Nat. Rev. Immunol, 14, 154, 10.1038/nri3605 Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat. Rev. Immunol, 9, 162, 10.1038/nri2506 Tan, 2006, Mechanisms of transcoelomic metastasis in ovarian cancer, Lancet Oncol, 7, 925, 10.1016/S1470-2045(06)70939-1 Winiarski, 2013, Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling, Transl. Oncol, 6, 703, 10.1593/tlo.13529 Gerhardt, 2003, VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia, J. Cell Biol, 161, 1163, 10.1083/jcb.200302047 Eilken, 2010, Dynamics of endothelial cell behavior in sprouting angiogenesis, Curr. Opin. Cell Biol, 22, 617, 10.1016/j.ceb.2010.08.010 Folkman, 1990, What is the evidence that tumors are angiogenesis dependent?, J. Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4 Abu-Jawdeh, 1996, Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms, Lab. Invest, 74, 1105 Hazelton, 1999, Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy, Clin. Cancer Res, 5, 823 Folkman, 2001, A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression, J. Natl Cancer Inst, 93, 734, 10.1093/jnci/93.10.734 Abulafia, 1997, Angiogenesis in primary and metastatic epithelial ovarian carcinoma, Am. J. Obstet. Gynecol, 177, 541, 10.1016/S0002-9378(97)70143-1 He, 2015, Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis, Asian Pac. J. Cancer Prev, 16, 869, 10.7314/APJCP.2015.16.3.869 Abulafia, 2000, Angiogenesis in early-invasive and low-malignant-potential epithelial ovarian carcinoma, Obstet. Gynecol, 95, 548 Armulik, 2005, Endothelial/pericyte interactions, Circ. Res, 97, 512, 10.1161/01.RES.0000182903.16652.d7 Crisan, 2008, A perivascular origin for mesenchymal stem cells in multiple human organs, Cell Stem Cell, 3, 301, 10.1016/j.stem.2008.07.003 Feng, 2011, Dual origin of mesenchymal stem cells contributing to organ growth and repair, Proc. Natl. Acad. Sci. U.S.A., 108, 6503, 10.1073/pnas.1015449108 Bergers, 2003, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest, 111, 1287, 10.1172/JCI200317929 Cooke, 2012, Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway, Cancer Cell, 21, 66, 10.1016/j.ccr.2011.11.024 Xian, 2006, Pericytes limit tumor cell metastasis, J. Clin. Invest, 116, 642, 10.1172/JCI25705 Sinha, 2016, Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients, Clin. Cancer Res, 22, 1813, 10.1158/1078-0432.CCR-15-1931 Stone, 2012, Paraneoplastic thrombocytosis in ovarian cancer, N. Engl. J. Med, 366, 610, 10.1056/NEJMoa1110352 Davis, 2014, Platelet effects on ovarian cancer, Semin. Oncol, 41, 378, 10.1053/j.seminoncol.2014.04.004 Gungor, 2009, The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors, Arch. Gynecol. Obstet, 279, 53, 10.1007/s00404-008-0673-9 Holmes, 2009, Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis, Clin. Exp. Metastasis, 26, 653, 10.1007/s10585-009-9264-9 Baccelli, 2013, Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay, Nat. Biotechnol, 31, 539, 10.1038/nbt.2576 Orellana, 2015, Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells, BMC Cancer, 15, 290, 10.1186/s12885-015-1304-z Raman, 2011, Chemokines in health and disease, Exp. Cell Res, 317, 575, 10.1016/j.yexcr.2011.01.005 Kulbe, 2007, The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells, Cancer Res, 67, 585, 10.1158/0008-5472.CAN-06-2941 Nash, 1999, The role of cytokines in both the normal and malignant ovary, Endocr. Relat. Cancer, 6, 93, 10.1677/erc.0.0060093 Zlotnik, 2000, Chemokines: a new classification system and their role in immunity, Immunity, 12, 121, 10.1016/S1074-7613(00)80165-X Jiang, 2006, Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression, Gynecol. Oncol, 103, 226, 10.1016/j.ygyno.2006.02.036 Kulbe, 2012, A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment, Cancer Res, 72, 66, 10.1158/0008-5472.CAN-11-2178 Balkwill, 2006, TNF-alpha in promotion and progression of cancer, Cancer Metastasis Rev, 25, 409, 10.1007/s10555-006-9005-3 Piura, 2014, Distinct expression and localization of TNF system in ovarian carcinoma tissues: possible involvement of TNF-alpha in morphological changes of ovarian cancerous cells, Anticancer Res, 34, 745 Scotton, 2001, Epithelial cancer cell migration: a role for chemokine receptors?, Cancer Res, 61, 4961 Scotton, 2002, Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer, Cancer Res, 62, 5930 Kajiyama, 2008, Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma, Int. J. Cancer, 122, 91, 10.1002/ijc.23083 Kumar, 2014, Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications, Biochim. Biophys. Acta, 1845, 117 Scambia, 1995, Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer, Br. J. Cancer, 71, 354, 10.1038/bjc.1995.71 Lutgendorf, 2008, Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients, J. Clin. Oncol, 26, 4820, 10.1200/JCO.2007.14.1978 Obata, 1997, Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma, Anticancer Res, 17, 337 Alberti, 2012, Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer, Oncogene, 31, 4139, 10.1038/onc.2011.572 Wang, 2012, Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells, Cytokine, 59, 228, 10.1016/j.cyto.2012.04.020 Lu, 2012, The extracellular matrix: a dynamic niche in cancer progression, J. Cell Biol, 196, 395, 10.1083/jcb.201102147 Davies, 2004, Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer, Clin. Cancer Res, 10, 5178, 10.1158/1078-0432.CCR-03-0103 Sanderson, 2001, Heparan sulfate proteoglycans in invasion and metastasis, Semin. Cell Dev. Biol, 12, 89, 10.1006/scdb.2000.0241 Sironen, 2011, Hyaluronan in human malignancies, Exp. Cell Res, 317, 383, 10.1016/j.yexcr.2010.11.017 Jojovic, 2002, Expression of hyaluronate and hyaluronate synthase in human primary tumours and their metastases in scid mice, Cancer Lett, 188, 181, 10.1016/S0304-3835(02)00037-X Anttila, 2000, High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer, Cancer Res, 60, 150 Tamada, 2012, Cell surface expression of hyaluronan on human ovarian cancer cells inversely correlates with their adhesion to peritoneal mesothelial cells, Tumour Biol, 33, 1215, 10.1007/s13277-012-0369-4 Kamat, 2006, The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer, Clin. Cancer Res, 12, 1707, 10.1158/1078-0432.CCR-05-2338 Hu, 2012, Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion, Arch. Gynecol. Obstet, 286, 1537, 10.1007/s00404-012-2456-6 Huang, 2002, Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice, J. Natl Cancer Inst, 94, 1134, 10.1093/jnci/94.15.1134 Kessenbrock, 2010, Matrix metalloproteinases: regulators of the tumor microenvironment, Cell, 141, 52, 10.1016/j.cell.2010.03.015 Bourboulia, 2010, Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion, Semin. Cancer Biol, 20, 161, 10.1016/j.semcancer.2010.05.002 Fu, 2015, The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer, Int. J. Gynecol. Cancer, 25, 356, 10.1097/IGC.0000000000000386 Zhang, 2013, Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance, Oncol. Rep, 29, 637, 10.3892/or.2012.2148 Borgfeldt, 2001, Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1), Int. J. Cancer, 92, 497, 10.1002/ijc.1215 Al-Hassan, 2012, Differential roles of uPAR in peritoneal ovarian carcinomatosis, Neoplasia, 14, 259, 10.1593/neo.12442 Giusti, 2008, Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles, Neoplasia, 10, 481, 10.1593/neo.08178 Zhang, 2014, Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer, Oncol. Rep, 31, 1334, 10.3892/or.2014.2967 Winiarski, 2014, Clinical relevance of increased endothelial and mesothelial expression of proangiogenic proteases and VEGFA in the omentum of patients with metastatic ovarian high-grade serous carcinoma, Transl. Oncol, 7, 267, 10.1016/j.tranon.2014.02.013 Baekelandt, 1999, The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer, Ann. Oncol, 10, 1335, 10.1023/A:1008352502465 Ferrandina, 1998, Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome, Br. J. Cancer, 78, 1645, 10.1038/bjc.1998.737 Chai, 2012, The potential prognostic value of cathepsin D protein in serous ovarian cancer, Arch. Gynecol. Obstet, 286, 465, 10.1007/s00404-012-2318-2 Saiki, 1997, Cell adhesion molecules and cancer metastasis, Jpn J. Pharmacol, 75, 215, 10.1254/jjp.75.215 Hynes, 2002, Integrins: bidirectional, allosteric signaling machines, Cell, 110, 673, 10.1016/S0092-8674(02)00971-6 Carduner, 2014, Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on alphav integrins, Clin. Exp. Metastasis, 31, 675, 10.1007/s10585-014-9658-1 Xue, 2013, Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by alphavbeta6 integrin-mediated signaling in ovarian cancer, Mol. Cell. Biochem, 380, 177, 10.1007/s11010-013-1671-1 Casey, 2001, Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids, Am. J. Pathol, 159, 2071, 10.1016/S0002-9440(10)63058-1 Mitra, 2011, Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis, Oncogene, 30, 1566, 10.1038/onc.2010.532 Bacic, 2013, Prognostic role of E-cadherin in patients with advanced serous ovarian cancer, Arch. Gynecol. Obstet, 287, 1219, 10.1007/s00404-012-2684-9 Strobel, 1997, In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation, Cancer Res, 57, 1228 Kayastha, 1999, Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival, Clin. Cancer Res, 5, 1073 Ross, 2001, Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas, Am. J. Clin. Pathol, 116, 122, 10.1309/KUK0-1M3D-LGNE-THXR Sillanpaa, 2003, CD44 expression indicates favorable prognosis in epithelial ovarian cancer, Clin. Cancer Res, 9, 5318 Bretz, 2013, Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling, J. Biol. Chem, 288, 36691, 10.1074/jbc.M113.512806 Battke, 2011, Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC, Cancer Immunol. Immunother, 60, 639, 10.1007/s00262-011-0979-5 Peng, 2011, Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity, Oncol. Rep, 25, 749 Cho, 2011, Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts, Gynecol. Oncol, 123, 379, 10.1016/j.ygyno.2011.08.005 Lis, 2012, Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties, PLoS ONE, 7, 10.1371/journal.pone.0038340 Szajnik, 2010, Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg), PLoS ONE, 5, 10.1371/journal.pone.0011469 Gutwein, 2005, Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells, Clin. Cancer Res, 11, 2492, 10.1158/1078-0432.CCR-04-1688 Runz, 2007, Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM, Gynecol. Oncol, 107, 563, 10.1016/j.ygyno.2007.08.064